ACADIA Pharmaceuticals (NASDAQ:ACAD) Director James Daly Sells 30,000 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director James Daly sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $22.37, for a total transaction of $671,100.00. Following the transaction, the director owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. This represents a 88.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.41 on Wednesday, hitting $24.13. The stock had a trading volume of 2,390,518 shares, compared to its average volume of 2,153,138. The stock has a 50 day moving average of $22.51 and a 200 day moving average of $22.11. The firm has a market capitalization of $4.08 billion, a P/E ratio of 18.14, a PEG ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The business had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. During the same period last year, the company earned $0.20 EPS. The firm’s revenue was up 11.3% compared to the same quarter last year. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Comerica Bank raised its holdings in ACADIA Pharmaceuticals by 4,770.1% during the first quarter. Comerica Bank now owns 43,100 shares of the biopharmaceutical company’s stock worth $716,000 after buying an additional 42,215 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of ACADIA Pharmaceuticals by 100.9% during the first quarter. Rhumbline Advisers now owns 352,716 shares of the biopharmaceutical company’s stock valued at $5,859,000 after buying an additional 177,188 shares during the last quarter. Atria Investments Inc increased its position in shares of ACADIA Pharmaceuticals by 26.1% during the second quarter. Atria Investments Inc now owns 22,087 shares of the biopharmaceutical company’s stock worth $476,000 after acquiring an additional 4,574 shares in the last quarter. Woodline Partners LP raised its holdings in shares of ACADIA Pharmaceuticals by 1,003.0% in the 1st quarter. Woodline Partners LP now owns 295,210 shares of the biopharmaceutical company’s stock worth $4,903,000 after acquiring an additional 268,445 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter worth about $511,000. 96.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ACAD has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft set a $29.00 target price on ACADIA Pharmaceuticals in a research report on Thursday, September 25th. Weiss Ratings reissued a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. The Goldman Sachs Group increased their price objective on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a “sell” rating in a research report on Thursday, August 7th. Finally, JPMorgan Chase & Co. lowered their target price on shares of ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $28.94.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.